Francisco Partners, a leading technology-focused private equity firm, today announced it has signed a definitive agreement to sell Aesynt to Omnicell, Inc.
“It has been a true pleasure to partner with the Aesynt management team to transform the business,” said Chris Adams, partner at Francisco Partners and chairman of the Aesynt board of directors.
“Through significant investment in new products – particularly new enterprise medication management software – the team significantly revitalized the organization and returned it to rapid growth.”
Aesynt enables health systems to reduce cost and improve patient safety through the integration, automation, and management of medication preparation and delivery system-wide with the industry’s most comprehensive medication management portfolio.
“Francisco Partners provided valuable strategic support, capital, and resources that allowed us to execute on a strategic vision that fueled new growth,” said Kraig McEwen, Aesynt CEO.
“Today, healthcare organizations embrace Aesynt’s robust medication management tools, which will complement Omnicell’s product portfolio and international footprint.”
“Aesynt brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics,” said Randall Lipps, CEO of Omnicell.
“We expect that as a combined entity we can accelerate innovation in the marketplace by leveraging the combined strengths of the Aesynt and Omnicell teams. Choice, innovation and value make this a great acquisition for Omnicell and our customers.”
Omnicell’s financial advisor in this transaction was Greenhill & Co LLC and Sidley Austin LLP, Cooley LLP and Jones Day served as legal counsel. Francisco Partners was advised by Robert W. Baird & Co. and Kirkland & Ellis LLP.